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Abstract
Background: A large proportion of treated hypertensive subjects do not achieve target blood pressure (BP) levels.
We investigated trends in treatment and BP levels in the population, and among treated hypertensive subjects in
northern Sweden.
Methods: The six Northern Sweden MONICA population surveys 1986 to 2009, included 6342 subjects aged
45 to 74 years of age, participation rate 79.3 %. Factors associated with lack of BP control are presented for 1106
participants in 2009. BP control was defined as a systolic BP <140 and a diastolic BP <90 mm Hg among treated
hypertensive patients.
Results: Between 1986 and 2009, the proportion of the population that received antihypertensive treatment increased.
The proportion of the whole population having BP <140/90 mm Hg increased for all (p < 0.001 for each subgroup),
except for men 45–55 years old. In 2009, 62.4 % of the population had BP <140/90 mm Hg, 67.2 % in women and
58.1 % in men (p = 0.002). In the group of treated hypertensive patients, the proportion having BP control increased
(p < 0.001) with no difference between sex or age groups. In 2009 52.1 % of treated hypertensives had BP control.
In 2009, adequate BP control among treated hypertensive patients was 63.9 % for those with BMI <25, but only 48.8 %
for those with BMI > 25 (p = 0.015). Abdominal obesity was associated with less BP control (48.1 %) than without
abdominal obesity (66.2 %, p = 0.007). Women who were physically inactive had better BP control than those who
were active (p = 0.03). Men treated with two or more antihypertensive drugs were 50 % more likely to reach target BP
than men with monotherapy (60.4 % vs. 40.0 %, p = 0.035). Rural or urban living, level of education, diabetes mellitus or
having a high cardiovascular risk were not associated with better BP control.
Conclusion: Antihypertensive treatment and BP control have increased in northern Sweden since 1986, although in
2009 still barely half of the treated patients achieved adequate BP levels. Intensified treatment and weight reduction
may help to further improve BP control.
Keywords: Cohort blood pressure hypertension trend
Background
High blood pressure (BP) is estimated to cause 9.4 mil-
lion premature deaths throughout the world each year
and has the highest attributable mortality of cardiovas-
cular risk factors [1]. It almost triples the risk for all
subtypes of stroke and myocardial infarction [2]. An in-
crease of 20 mm Hg in systolic, or 10 mm Hg in
diastolic BP, doubles the risk of dying from stroke or is-
chemic heart disease [3]. Although hypertension is
largely amendable through adequate antihypertensive
treatment [4], more than two thirds of the treated hyper-
tensive population in the world continue to have BP
levels above the target limit [5].
According to the 2013 guidelines from the European
Society for Hypertension and the European Society for Car-
diology, treatment should be considered for subjects at high
cardiovascular risk, until the BP is below 140/90 mmHg
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[6]. During the 1990s, 54 % of treated hypertensive patients
in the US and only 19 to 40 % in Europe had controlled BP
(defined as BP <140/90 mm Hg) [7]. Only 32 % of treated
hypertensives worldwide between 35 and 70 years reached
this target BP [5].
The multinational MONICA study between 1986 and
1994 compared hypertension control between 24 areas
and found that subjects treated for hypertension in
northern Sweden were among those with the lowest
prevalence of control [8]. In the county of Västerbotten
in northern Sweden, treatment increased in the popula-
tion between 1990 and 2010, and control among treated
increased to 65 % in 2009 [9]. Sex, education level and
number of drugs for hypertension are among factors
proposed to determine control rates [7, 9–12].
Reliable and recent data on BP control from well stan-
dardised and validated population studies are lacking.
Because use of anti-hypertensive medication increased
markedly in northern Sweden in the mid-1990s [13], we
aimed to describe how, and if, this influenced the con-
trol of hypertension between 1986 and 2009. We also in-
vestigated factors possibly associated with lack of control
among the treated patients today and looked for factors
that might be amendable to the health care system or
lifestyle changes.
Methods
Our analysis is based on the six surveys in the Northern
Sweden MONICA study. The first survey took place in
the early spring of 1986, and the following five surveys
were conducted at the same time of the year, and the
most recent took place in 2009. Similar procedures for
sampling, anthropometric measurements and blood
pressure were used throughout the whole study.
Participants
Details of sampling and selection have been presented
previously [14]. The participants were randomly selected
from population registers in the two most northern
counties of Sweden (target population 312 000) [13]. For
each survey the subjects were age-stratified into 10-year
age groups (25 to 74 years) with a total of 250 men and
women in each stratum. In this analysis, only subjects
between 45 and 74 years of age were included due to the
low prevalence of treated hypertensive patients among
the younger participants. For the 1986 and 1990 surveys
only data for subjects 45 to 64 years were available.
Through telephone interviews we evaluated non-responder
bias [14]. In the first three surveys, non-responders were
more likely to be obese or hypertensive, more likely to
smoke, but had a similar educational level. In 2009 non-
participants were younger, had lower education and more
often were smokers or diabetics.
The study was approved by the Research Ethics
Committee of Umea University, and all subjects gave in-
formed consent to participate.
Measurement procedures
Details regarding survey procedures have been published
[14]. The teams conducting the examinations were specially
trained by the same instructors to ensure correctness and
consistency. Information regarding life style, social and med-
ical history were extracted from material collected by survey
questionnaires. BP was measured twice in sitting position,
after a 5-min rest, using the Hawksley random-zero
sphygmomanometer, the mean value was recorded [15].
Control among treated hypertensive subjects was defined
as having a systolic BP of <140 and a diastolic BP <90 mm
Hg. Current antihypertensive drug treatment was deter-
mined by asking: “Are you taking (in the last 2 weeks)
drugs for high BP?” [14]. Physical activity was defined as ex-
ercising on a regular basis or not. “Regular exercise” ranges
from light exercise twice a week to high intensity/vigorous
workout several times a week. “No regular exercise”
included subjects performing occasional low-intensity exer-
cise or not exercising at all. Urban or rural living was deter-
mined by the population size of the community; >15 000
inhabitants was considered to be urban and ≤15 000 rural.
“Educational level” was defined as having attended univer-
sity or not.
Normal weight was defined as BMI <25, overweight as
BMI 25–29,9, and obesity as BMI of 30 or aboveAbdom-
inal obesity was defined as a waist circumference of 94 cm
or more for men, 80 cm or more for women. High cardio-
vascular risk was defined by self-reported previous stroke,
myocardial infarction, coronary surgery, or having dia-
betes. Onehundred and sixty nine of the 6229 subjects
had high cardiovascular risk (15.2 %). Number of antihy-
pertensive drugs was defined as using 1 or >1 BP-lowering
drug(s), based on self-reported information.
Predictors and factors associated with lack of BP con-
trol are only presented for the 2009 participants.
Statistical methods
Data are presented as means or proportions with 95 %
confidence intervals (CI). Time trends for categorial var-
iables were analyzed by Chi-square test for linear trends.
Univariable och multivariable logistic regression was
used to analyze the association between age, sex and
other factors potentially associated with hypertension
control. Two-by-two interaction terms including age
group or sex were added to the regression model to
study if effects of other factors varied by age or sex.
Results
In the six MONICA population surveys between 1986
and 2009, 8000 subjects between 45 and 74 years of age
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were invited. 6342 subjects (79.3 %) participated, 50.1 %
women and 49.9 % men. BP values were missing in six
subjects and data on treatment with BP lowering drugs
were missing in 108 subjects leaving 6229 subjects in-
cluded in the statistical analyses. For 44 subjects treated
with BP lowering drugs, the exact numbers and type of
drugs were not known.
Trends in treatment and control 1986 to 2009
From 1986 to 1994, the use of BP lowering drugs
remained steady or even decreased in some age groups,
but the use subsequently increased (p <0.001 for the
whole population 45 to 74 years) (Fig. 1). The tendency
was similar for men and women and in the different age
groups with no interaction between sex or age group
and year of survey.
Between 1986 and 2009, the proportion having BP con-
trol (<140/90 mm Hg) increased in the whole population
(p < 0.001). The effect differed by age group (p <0.001) but
not by sex (Fig. 2). The increase was evident in all age and
sex strata except for the youngest men (p < 0.001).
In 2009, BP control among subjects 45–74 years was
62.4 %, and more prevalent in women (67.2 %) than in
men (58.1 % p = 0.002) (Table 1).
After an initial decrease, BP control increased rapidly
in the whole group of treated hypertensive subjects (p <
0.001) (Fig. 3). This trend did not differ by sex or age
group.
Factors associated with inadequate BP control in 2009
In the 2009 MONICA survey, 1106 subjects aged 45–74
years participated with fairly equal numbers in each age
stratum and between genders (Table 1). Fifteen hundred
subjects were invited and thus the participation rate was
73.7 %. Treatment with BP lowering drugs in the popu-
lation was 29 %, with no difference betweeen men and
women. An average of 1.77 BP lowering drugs was used.
The most commonly used antihypertensive drugs acted
on the RAA-system (used by 59.5 %), followed by beta-
adrenergic blockers (52.4 %), diuretics (including tia-
zides, loop diuretics and spironolactone) (38.3 %) and
calcium channel blockers (27.3 %).
Among the 313 treated hypertensive subjects, 52.1 %
had adequate BP control.
The difference in BP control between men and women
was negligible, 52.8 % men vs. 51.3 % women, and there
was no differerence by age group (Table 1).
One fifth (20.3 %) of the population aged 45–74 years
was physically inactive in 2009. Almost a quarter of the
subjects treated with BP lowering drugs were inactive.
Physically active women had less BP control than physic-
ally inactive women (46.0 vs. 66.7 %, p = 0.03). There
was no association between degree of physical activity
and BP control among men. A test for interaction con-
firmed that the effect differed by sex (p = 0.028). There
was a fairly equal distribution of subjects living in rural
vs. urban communities, and BP control did not differ be-
tween them.
In 2009, 16 % of the population aged 45–74 years used
one anti-hypertensive drug and 11 % used two or more.
In the treated patients, approximately 40 % used two or
more drugs. Treatment with a combination of BP lower-
ing drugs was more common among older patients.
Among all treated hypertensives, treatment with one vs.
two drugs or more was not associated with any differ-
ence in BP control, 48.3 vs. 55.4 % (p = 0.3). Among
Fig. 1 Time trend in prevalence of treatment 1986 to 2009, by gender (a: women, b: men) and age group
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women no difference was seen, but among men the cor-
responding figures were 40.0 % and 60.4 %, respectively
(p = 0.035).
Three quarters of the subjects had not attended uni-
versity and were defined as having a lower level of edu-
cation, and that proportion was similar in subjects with
or without treatment for hypertension. There were no
differences in BP control according to level of education
among hypertensive subjects. BP control did not differ
between subjects with or without diabetes, 63.0 vs.
49.6 % (p = 0.07).
Among the entire 6229 subjects, 22 % were obese and
43 % were overweight. The use of BP lowering drugs in-
creased with BMI, and among men and women with
obesity, nearly 50 % used antihypertensives. BP control
did not differ across the three BMI categories. When
merging the overweight and obese groups, BP control
was found in 64 % of the normal weight subjects, but in
only 49 % of the overweight + obese group (p = 0.024).
Almost two thirds had abdominal obesity, more so
among subjects treated with antihypertensives (59.2 vs.
77.2 %). Only 48.1 % of the subjects with abdominal obes-
ity had BP control, whereas the corresponding figure for
those without abdominal obesity was 66.2 % (p = 0.007).
Among the entire 6229 subjects, 15.2 % were classified
as having a high cardiovascular risk, defined as having
had a previous stroke, myocardial infarction, coronary
surgery, or having self-reported diabetes. Among those
treated with BP lowering drugs, 30.3 % had a high car-
diovascular risk. There was no association between BP
control and having a high cardiovascular risk.
When adjusting for age (as a continous variable) and sex
in a logistic regression, none of the variables – physical in-
activity, rural living, number of BP lowering drugs, level of
education or high cardiovascular risk – were associated
with BP control. Overweight and obesity were associated
with less BP control (p = 0.023, OR 1.89, 95 % CI 1.09;
3.25), and abdominal obesity was also associated with less
BP control (p = 0.008, OR 2.1, 95 % CI 1.2; 3.7).
Discussion
Antihypertensive treatment increased in northern Sweden
between 1986 and 2009, which may partly explain why the
proportion having BP control (BP <140/90) increased both
in the population and among the treated hypertensive
subjects. Since almost half of the treated subjects did not
reach target levels we searched for characteristics that
would be amendable to the health care system or to life-
style changes. Inadequate BP control in 2009 was not
signficantly associated with gender or age, but it was asso-
ciated with overweight or general and abdominal obesity.
In men, using two or more antihypertensive drugs was as-
sociated with better BP control. Other socioeconomic, life
style and treatment-related factors did not contribute to
better control, although the low numbers in these sub-
groups should caution against strong conclusions.
Trends toward increased BP treatment were seen in al-
most all groups, most noticeably after 1994, as previ-
ously reported [13]. Similar trends are reported from the
US [16]. In 2009, the use of antihypertensive medication
in the older population in northern Sweden was some-
what less common (Sweden 45 %) than in Canada
(52 %) [12]. Recent studies in Europe report treatment
rates in the population >20 years of age around 10 % to
just above 40 % [9, 10, 17–19], which are comparable to
our 30 % treatment level.
Until the mid 1990s, many Swedish physicians were
reluctant to treat otherwise healthy individuals with BP
Fig. 2 Proportions of subjects with BP <140/90 in the population and time trends from 1986 to 2009, by gender (a: women, b: men) and age group
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lowering drugs. Early results from the MONICA project
showed a higher rate of cardiovascular events in
northern Sweden than in many other western European
countries, which probably lead to a change in attitude
and an intensification of antihypertensive treatment in
the mid-1990s in Sweden [20, 21]. The publication from
the Swedish Health Technology Assessment Agency in
1994, Moderately Elevated BP, updated in 2004 [22],
emphazised risk stratification and the use of more
than one drug. Therefore a greater focus was put on
adequate case finding, life style advice and treatment
to target levels.
BP trends in the whole population mirror the effects
of medical treatment of some subjects and possibly also
the influence of factors in the society such as increasing
obesity, changes in diet and changes in physical activity.
In 2000, BP control in the population in northern
Sweden was less than in the USA [16]. A Swiss study re-
ported 73 % BP control in 2009 compared with 63 % the
same year in MONICA [23]. A Canadian study found
79 % BP control among 60–79 years olds in 2009, which
was better than the 55 % among elderly in northern
Sweden in 2009 [12]. Thus, a concerted action to lower
BP in the general population of Sweden with both life
style changes and drug treatment is warranted.
Trends towards better control among treated hyperten-
sive patients were seen in several countries. In this study,
BP control increased rapidly and reached 52 % in 2009.
That was greater than that reported in Lithuania and
Denmark [10, 24], similar to that reported in the US 2000
and Italy in 2012, but below that found in Switzerland
2009 (59 %) [16, 17, 23] and far lower than that reported
in Canada in 2009 (73 % 60–79 years) [12].
Sex had no effect on BP control in our study, and re-
sults in the literature vary. Some studies show women
are more likely to have BP control [7, 9, 10, 23], while
others find that men are more likely to have BP control
[8, 12, 16].
Age would be expected to increase blood pressure be-
cause blood vessels become stiffer and glomerular filtra-
tion rate decreases with age, which would affect the
response to treatment [6, 25, 26]. BP-lowering drugs are
less well tolerated among older subjects, which leads to
a more restrictive attitude from physicians towards treat-
ment and BP goals [27]. However, we found no effect of
age on BP control. Some studies have found no effect of
age [23], while others have found better BP control in
the elderly [12, 28, 29]. Among those reporting less BP
control among older subjects, it seems like elderly
women have less BP control than men [12, 16].
Self reported physical activity was lower among women
with good BP control than women with poor BP control
in our study. Perhaps women with too little effect from
their BP treatment or with refractory hypertension pur-
posely exercise more to try to improve their BP control.
Similar results were recently reported from Canada [12],
but in Switzerland and Spain a sedentary lifestyle was as-
sociated with less satisfactory BP control [23, 30].
Large areas in northern Sweden are sparsely popu-
lated, and the long distances might lead to difficulties to
obtain healthcare, which could lead to infrequent con-
tact with health care personnel, poor detection of illness
and poor follow-up of disorders such as hypertension.
Even so, we found no association between BP control
and size of communityThis indicates that health care in
northern Sweden manages to provide care of equal
Table 1 Sample sizes and prevalences of hypertension,
treatment and control in 2009
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quality regardless of living conditions for people with
hypertension, and this is corroborated by a recent study
in Poland [28].
Multiple antihypertensive drugs in men induced better
BP control than monotherapy in our study, but only a
minority used two or more drugs. In contrast, another
Swedish study found better BP control among people
treated with monotherapy [31]. Perhaps patients with
multiple antihypertensive drugs have a more severe and/
or refractory hypertension, i.e. confounding by indication
in non-randomized cohort studies. Recently published
randomized control trials support our findings, present
similar advantages with combination therapy, and
emphasize the benefit from initial combination therapy,
as the effect might be reduced if initiated later on [32].
Physicians might have an over-reliance on monotherapy,
or reluctance towards combination therapy, which could
explain why hypertensives continue to receive mono-
therapy despite inadequate BP control [11]. As many as
95 % of people with hypertension might be able to reach
target BP, mainly through combination therapy [4].
Socioeconomic characteristics determine many traits
of disease and response to treatment, but we found no
association between educational level, as a proxy for so-
cioeconomic status, and BP control. Some studies show
no effect of educational level on BP controll whereas
others show somewhat better BP control with higher
education [9, 12, 23, 28, 33].
The aetiology behind type-2 diabetes and the cardio-
vascular and renal complications that follow type-2 dia-
betes, may reduce the efficacy of treatment among older
diabetics and make it more difficult to achieve BP
control. Some studies show no association between hav-
ing diabetes and BP control [18, 23, 34], whereas others
show poorer BP control among diabetics [35]. Since
hypertension in diabetics increases the risk of both car-
diovascular disease and end stage renal diseases, it is dis-
appointing that BP control is so often lacking among
diabetics.
Obesity and overweight were associated with poorer
BP control than normal weight. Arterial stiffness, which
is a consequence of diet-induced obesity, precedes and
may contribute to the development of hypertension [36].
This association may explain why arterial stiffness is not
found to the same extent among people with essential
hypertension, as among those with obesity, isolated sys-
tolic hypertension, chronic kidney disease and old age
[37]. Results similar to ours were observed in a study
from Poland [28] but not in Swizerland or Canada [12, 23]
where control rates were higher than in northern Sweden.
This indicates a more offensive approach when treating
hypertensive patients until reaching goal BP. This may es-
pecially benefit people with obesity.
Abdominal obesity was associated with markedly de-
creased BP control in our study. In a Chinese study, BMI,
and not abdominal obesity, was more related to poor BP
controll [38]. Endocrine secretion differs between intra-
abdominal and subcutaneous fat [39]. Adipokines, bio-
active peptides and proteins released from intra-abdominal
fat, are fundametal in the pathogenesis of the metabolic
syndrome and probably also in atherosclerosis. Intra-
abdominal adipose tissue secrets high levels of a precursor
to angiotensin II, which is known to cause BP elevation.
Specific properties of intra-bdominal fat may block the
Fig. 3 Time trend in BP control among subjects treated 1986 to 2009, by gender (a: women, b: men) and age group
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effect of antihypertensive drugs and contribute to hyper-
tension. Therefore, abdominal obesity is an independent
predictor of resistant hypertension [40]. Abdominal obesity
was the only predictor regarding deficient control that was
found among both men (second largest impact of the fac-
tors observed) and women (largest impact) in an elderly
population of Stockholm [31]. Studies on abdominal obes-
ity as a predictor of BP control are scarce, and futher re-
search is merited due to its strong impact.
We found no association between having a high car-
diovascular risk and hypertension control. It is desirable
that a substantially larger proportion of people with high
cardiovascular risk achieve target BP levels to avoid fur-
ther cardiovascular events, since lowering BP might be
of greatest absolute benefit for them [35]. In other stud-
ies poorer BP control rates were found among hyperten-
sive patientes with cardiovascular diseases [35], whereas
previous myocardial infarction and/or angina pectoris
were associated with increased BP control rates [31].
A major strength In the Northern Sweden MONICA
study is its strict and uniform methodology throughout
the whole time period from 1986 to 2009. BP readings
by random-zero methods avoid digit preference and an-
thropometry measurements were made by trained staff
using similar equipment and protocols. Comparisons be-
tween BP measurements with random-zero and an auto-
mated oscillometric device, show higher accuracy in
favour of random-zero measurement methods [15].
Note that patients with white-coat hypertension were
not correctly diagnosed using the mean of 2 BP mesure-
ments. However, the aim of this study was not to diag-
nose clinical hypertension. We aimed to describe an
epidemiological picture of hypertension in the popula-
tion, using methods common with all major population
studies. Another limitation is that information given in a
questionnare can be inaccurate and self-reported phys-
ical activity was probably the least reliable variable. In
addition, there has been a declining participation rate in
the Northern Sweden MONICA Study, from 81 % to
69 % over the study period, and this is almost entirely
due to the loss of younger men and women [14]. In the
age groups now studied we had a high participation rate,
79.3 %, which supports the validity of our data. Non-
significant effects may be due to the relatively low sam-
ple size in some sub groups.
Conclusions
In conclusion, antihypertensive treatment increased in
northern Sweden between 1986 and 2009, most evident
among the elderly. A probable consequence of that is
that BP control has increased in the population and
among treated hypertensives. Even so, further effort is
needed since several studies show that it is possible to
achieve far higher BP control rates. The health care
systems are similar in Sweden and Canada, and both are
mainly tax funded [41]. In Canada, more than 90 % of
the hypertensive patients are treated and 80 % reach the
BP goal. It should be possible for Sweden to reach the
same treatment goals [12].
Overweight, obesity, and abdominal obesity are all as-
sociated with lack of BP control, thus making these
groups a target for intensified antihypertensive therapy.
If BP goals are not achieved promptly, it is reasonable to
try treatment with one or more additional antihyperten-
sive drugs, since it is possible to achieve a higher preva-
lence of control with combination therapy [4].
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